BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 157 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $68,000 | -36.4% | 6,421 | -2.5% | 0.00% | -100.0% |
| Q1 2022 | $107,000 | +23.0% | 6,587 | +5.5% | 0.00% | 0.0% |
| Q4 2021 | $87,000 | -22.3% | 6,246 | -20.1% | 0.00% | 0.0% |
| Q3 2021 | $112,000 | +36.6% | 7,817 | +50.5% | 0.00% | 0.0% |
| Q2 2021 | $82,000 | +54.7% | 5,193 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $53,000 | +20.5% | 5,193 | -11.2% | 0.00% | 0.0% |
| Q4 2020 | $44,000 | +76.0% | 5,850 | -17.6% | 0.00% | – |
| Q3 2020 | $25,000 | +47.1% | 7,100 | +104.5% | 0.00% | – |
| Q2 2020 | $17,000 | – | 3,472 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VHCP Management II, LLC | 6,071,142 | $38,430,000 | 18.43% |
| RTW INVESTMENTS, LP | 4,078,895 | $25,819,000 | 9.72% |
| VHCP Management, LLC | 1,155,104 | $7,312,000 | 7.86% |
| RA Capital Management | 2,989,795 | $18,925,000 | 2.68% |
| DLD Asset Management, LP | 1,258,700 | $7,967,000 | 2.61% |
| Avoro Capital Advisors LLC | 1,631,502 | $10,327,000 | 2.09% |
| Ghost Tree Capital, LLC | 1,150,000 | $7,280,000 | 1.75% |
| GREAT POINT PARTNERS LLC | 725,000 | $4,589,000 | 0.94% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,237,734 | $20,495,000 | 0.84% |
| Baker Brothers Advisors | 10,963,944 | $69,402,000 | 0.68% |